Literature DB >> 1386887

Actions of a 5-lipoxygenase inhibitor, Sch 40120, on acute inflammatory responses.

S R Smith1, A W Watnick, R W Bryant, M Billah, M I Siegel.   

Abstract

Sch 40120 (10-(3-chlorophenyl)-6,8,9,10-tetrahydrobenzo[b] [1,8]naphthyridin-5(7H)-one) is an inhibitor of the 5-lipoxygenase enzyme in rat neutrophils, human neutrophils and the the MC9 murine mast cell clone with IC50 values of 8, 4 and 7 microM, respectively. The drug was examined for its effects on acute inflammatory responses in the paw and pleural cavity of rats. The drug suppressed paw inflammation triggered by a reverse passive Arthus reaction or a subplantar injection of the polysaccharide carrageenan with p.o. ED50 values of 0.2 and 1.5 mg/kg, respectively. In reverse passive Arthus reaction and carrageenan pleurisy models, Sch 40120 was found to suppress both the cellular and fluid components of the acute inflammation. The p.o. ED50 values for inhibition of cells and fluid in pleurisy models were in the range of 0.1 to 0.7 mg/kg. When applied locally to the ears of mice, the drug blocked an arachidonic acid-induced and leukotriene-mediated ear inflammation with an ED50 of 0.072 mg/ear. These findings suggest that Sch 40120 is a potent anti-inflammatory agent that may be particularly useful in the treatment of inflammatory diseases such as psoriasis in which leukotrienes appear to be major mediators of the pathological symptoms that characterize the disease state.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386887

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Arachidonic acid (AA) and tetradecanoylphorbol acetate (TPA) exert systemic effects when applied topically in the mouse.

Authors:  V Puigneró; A Turull; J Queralt
Journal:  Inflammation       Date:  1998-06       Impact factor: 4.092

2.  2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo.

Authors:  C Greiner; C Hörnig; A Rossi; C Pergola; H Zettl; M Schubert-Zsilavecz; D Steinhilber; L Sautebin; O Werz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.

Authors:  T Uematsu; M Kanamaru; K Kosuge; K Hara; N Uchiyama; N Takenaga; W Tanaka; B S Friedman; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.